Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Hyperkalaemia
Interventions
DRUG

Sodium Zirconium Cyclosilicate (SZC)

Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.

OTHER

Enhanced dietary advice

Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.

OTHER

Standard dietary advice including K+ restriction.

Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.

Trial Locations (1)

33411

Research Site, West Palm Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY